TSX closed
Loading markets…

Advertisement

Stocks/TSX/CRDL

Cardiol Therapeutics Inc Class A (CRDL : TSX)

Common Stock

$1.59

CAD

-0.05 (-3.05%)

Last updated: 2026-10-23

Follow CRDL

CRDL

Cardiol Therapeutics Inc Class A

Source:WealthAwesomeWealthAwesome
↓ $1.16 (-42.18%)
30 day period
$1.57$2.17$2.77Sep 11Oct 2Oct 23

Performance

1 Day

-3.05%

1 Week

+0.63%

1 Month

-36.14%

YTD

+16.91%

Key Statistics

Market Cap

$193.21M

52W High

$3.23

52W Low

$1.23

P/E Ratio

-

50 Day MA

$2.39

200 Day MA

$1.81

Beta

0.72

Dividend Yield

-

Advertisement

Technical Indicators

Price vs 50-Day SMA

↓Below 50 SMA

Price vs 200-Day SMA

↓Below 200 SMA

Recent Price History

DateOpenHighLowCloseAdj CloseVolume
10/23/2026$1.65$1.65$1.55$1.59$1.59134,973
10/22/2026$1.66$1.67$1.61$1.64$1.64133,566
10/21/2026$1.63$1.66$1.62$1.66$1.66143,282
10/20/2026$1.57$1.64$1.54$1.63$1.63134,567
10/19/2026$1.57$1.58$1.53$1.57$1.5797,738
10/16/2026$1.62$1.62$1.54$1.58$1.58143,940
10/15/2026$1.64$1.65$1.60$1.60$1.60279,375
10/14/2026$1.70$1.70$1.60$1.60$1.60158,320
10/13/2026$1.75$1.76$1.68$1.71$1.71217,351
10/9/2026$1.87$1.88$1.77$1.78$1.78179,600

Analyst Price Targets

Based on analyst covering CRDL · as of Oct 12, 2026

📈

Wall Street analysts forecast CRDL stock price to rise 340.3% over the next 12 months.

Consensus

Bullish

Based on avg. target vs last close (formal rating unavailable for Canadian listings)

Avg. Target

C$7.00

+340.3% Upside

Previously C$6.00 on Sep 17, 2026

Current Price

C$1.59

Last close

Compare analyst targets →

Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.

Wealth Awesome Price Forecast

WA Model

Statistical 90-day price range based on CRDL's historical volatility

HistoricalForecast68%95%
C$0.77C$1.27C$1.76C$2.26C$2.76C$3.25TodayJun 16Aug 20Oct 23Dec 5Jan 18Mar 2

30-Day Vol

49.6%

Annualized

90-Day Vol

66.1%

Annualized

Trend (90d)

-28.1%

Annualized drift

90d Mean

C$1.44

Expected price

HorizonExpected68% Range (1σ)
30 trading daysC$1.54C$1.30 – C$1.82
60 trading daysC$1.49C$1.17 – C$1.89
90 trading daysC$1.44C$1.07 – C$1.93

Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.

About Cardiol Therapeutics Inc Class A

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38, a novel subcutaneously administered drug formulation of cannabidiol for the treatment of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.

Financials

Revenue (TTM)
$0
EBITDA
$-35.85M
Profit Margin
0.00%
ROE (TTM)
-190.18%
EPS (Diluted)
-0.35
Book Value
0.21

Classification

Sector
Health Care
Industry
Pharmaceuticals
Group
Pharmaceuticals, Biotechnology & Life Sciences

7 stocks to buy and hold forever

Blue-chip dividend stocks for long-term wealth building.

Get the FREE Report

Advertisement

Common Questions About CRDL

Market movers

Recent TSX movers

Top 1-day gainers — updated from our Canadian movers feed.

All movers →
TickerNamePrice1D
PNC-APostmedia Network Canada Corp$0.14+40.00%
EAGREast Side Games Group Inc$0.07+16.67%
CWEBCharlotte's Web Holdings Inc$0.36+10.61%
SNDYSunday Lake Gold Corp.$1.60+6.67%
GASXNG Energy International Corp.$1.01+6.32%
RVXResverlogix Corp.$0.09+5.88%
LAMLaramide Resources Ltd.$0.46+5.81%
BNEBonterra Energy Corp$6.82+5.74%

CRDL.TO news timeline

15 articles covering CRDL.TO, most recent first

Latest

Top penny stocks on the TSX & TSXV — October 15, 2026

•Investing

Advertisement